Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 229

Posts Tagged ‘investor’

20th Annual B. Riley FBR Institutional Investor Conference

Posted by fidest press agency su sabato, 18 maggio 2019

Smith Micro Software, Inc. (NASDAQ: SMSI) today announced that it will present at the 20th Annual B. Riley FBR Investor Conference, on May 22, 2019 from 11:30 a.m. PT to 11:55 a.m. PT. The conference will feature over 300 public and privately traded companies to highlight their successes to institutional investors, corporate clients and high net worth individuals. To access a live webcast of Smith Micro’s formal presentation, click here: Webcast.The conference is being held at The Beverly Hilton in Beverly Hills, California. For more information about the FBR Investor conference please contact your B. Riley FBR representative.Smith Micro develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers and cable MSOs around the world. From enabling the family digital lifestyle to providing powerful voice messaging capabilities, our solutions enrich today’s connected lifestyles while creating new opportunities to engage consumers via smartphones and consumer IoT devices. The Smith Micro portfolio also includes a wide range of products for creating, sharing and monetizing rich content, such as visual voice messaging, optimizing retail content display, performing analytics on any product set, and 2D/3D graphics applications. For more information, visit http://www.smithmicro.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Enanta Pharmaceuticals to Present at Upcoming Investor Conference

Posted by fidest press agency su giovedì, 16 maggio 2019

May 22, 1:35 p.m. ET; 2019 RBC Capital Markets Global Healthcare Conference, New York City. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation format at the investor conference.A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at http://www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).Enanta’s research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Everspin to Present at B. Riley FBR Institutional Investor Conference

Posted by fidest press agency su mercoledì, 15 maggio 2019

May 22. Everspin Technologies, Inc. (Nasdaq: MRAM), the market leader in MRAM, today announced Jeff Winzeler, CFO, will present at the B. Riley FBR Institutional Investor Conference to be held at the Beverly Hilton Hotel in Beverly Hills, CA. Management is scheduled to present on Wednesday, May 22nd at 8:00 a.m. PT and will be available throughout the day to meet with investors attending the conference.Portfolio managers and analysts who wish to request a meeting with management should contact their B. Riley FBR representative or send an email to conferences@brileyfbr.com. A live audio webcast and archived replay of the Company’s presentation will be made available in the Investor Relations section of the Company’s website at investor.everspin.com.
Headquartered in Chandler, Arizona, Everspin Technologies, Inc. is the worldwide leader in the design, volume production and distribution of Magnetoresistive RAM (MRAM) into markets and applications where data persistence, performance, and endurance are paramount. Serving applications across the data center, industrial, and transportation markets, Everspin has built the strongest and fastest-growing foundation of MRAM users in the world. For more information, visit http://www.everspin.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Avalara to Present at Upcoming Investor Conferences

Posted by fidest press agency su venerdì, 10 maggio 2019

Avalara, Inc. (NYSE:AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced the following upcoming investor conference presentations.
Co-Founder and Chief Executive Officer Scott McFarlane will present at the J.P. Morgan 47th Annual Global Technology, Media and Communications Conference in Boston on Thursday, May 16, 2019, at 10:40 a.m. ET (7:40 a.m. PT).
Chief Financial Officer Bill Ingram will present at the Needham Emerging Technology Conference in New York on Tuesday, May 21, 2019, at 1:50 p.m. ET (10:50 a.m. PT).
Live webcasts of the presentations will be available on the Avalara investor relations website at investor.avalara.com. Archived replays will be made available for a limited time at the same location following the presentations.
Avalara helps businesses of all sizes get tax compliance right. In partnership with leading ERP, accounting, ecommerce, and other financial management system providers, Avalara delivers cloud-based compliance solutions for various transaction taxes, including sales and use, VAT, GST, excise, communications, lodging, and other indirect tax types. Headquartered in Seattle, Avalara has offices across the U.S. and around the world in Canada, the U.K., Belgium, Brazil, and India. More information at http://www.avalara.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

DBV Technologies to Attend Upcoming Investor Conferences

Posted by fidest press agency su sabato, 4 maggio 2019

Montrouge, France DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present at the following investor conferences in May 2019:
Daniel Tassé, Chief Executive Officer, and Kevin Trapp, Chief Commercial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV, on Tuesday, May 14, 2019, at 11:20am PT.Kevin Trapp, Chief Commercial Officer, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, May 30, 2019, at 10:30am PT.A live webcast of the presentation at the Bank of America Merrill Lynch 2019 Health Care Conference will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website within one hour after the event.
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ProMIS Neurosciences to Participate in the Think Equity Investor Conference

Posted by fidest press agency su mercoledì, 24 aprile 2019

TORONTO and CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that it will participate in the Think Equity Investor Conference being held on May 2, 2019 at the Mandarin Oriental Hotel in New York.Eugene Williams, ProMIS’ Executive Chairman will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) at 10:30 am ET, in the Lotus West Room. In his talk Mr. Williams will also underline how the evaluation of novel biomarkers in patients will significantly accelerate drug development in neurodegenerative diseases. The video webcast and slides of Mr. Williams’ presentation will be available through the following link http://wsw.com/webcast/thinkequity/arfxf/. The webcast will be archived for 90 days following the event through the same link.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 4 aprile 2019

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will present a corporate overview at the H. C. Wainwright and Company Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. GMT at the Grosvenor House JW Marriott Hotel in London, UK and at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 2:50 p.m. ET at the Westin Grand Central Hotel in New York City.Live audio webcasts of both presentations will be available on the Company’s website at https://tphase.gcs-web.com/events-presentations. The archived presentation will be available for 30 days.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase’s lead product XERAVATM is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical trials and TP-2846 which is in preclinical testing for acute myeloid leukemia. Please visit http://www.tphase.com for more company information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ScanSource to Present at Sidoti & Company Spring 2019 Investor Conference

Posted by fidest press agency su martedì, 26 marzo 2019

New York city Thursday, March 28, 2019 12:55 p.m. Eastern Time ScanSource, Inc., (NASDAQ: SCSC), a leading global provider of technology products and solutions, announced plans to present at the Sidoti & Company Spring 2019 Investor Conference. The presentation will be available via a live audio webcast. A replay of the webcast will be archived and available for 7 days following the live presentation. To listen to the live audio webcast or replay, visit http://www.scansource.com (Investor Relations section).An investor presentation that will be used at the conference and upcoming investor meetings is posted in the Investor Relations section of the ScanSource, Inc. website, http://www.scansource.com.
ScanSource, Inc. (NASDAQ: SCSC) is a leading global provider of technology products and solutions, focusing on point-of-sale (POS), payments, barcode, physical security, unified communications and collaboration, cloud and telecom services. ScanSource’s teams provide value-added solutions and operate from two segments, Worldwide Barcode, Networking & Security, which includes POS Portal, and Worldwide Communications & Services, which includes Intelisys and Canpango. ScanSource is committed to helping its customers choose, configure and deliver the industry’s best solutions across almost every vertical market in North America, Latin America and Europe. Founded in 1992 and headquartered in Greenville, South Carolina, ScanSource was named one of the 2018 Best Places to Work in South Carolina and on FORTUNE magazine’s 2019 List of World’s Most Admired Companies. ScanSource ranks #653 on the Fortune 1000. For more information, visit http://www.scansource.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ResMed to Host an Investor Meeting

Posted by fidest press agency su lunedì, 25 marzo 2019

ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software.Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Space for the event is limited and therefore in-person attendance is available by invitation only.Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com. A replay of the webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible for approximately one year thereafter.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Aura Biosciences to Present at Upcoming Investor Conferences

Posted by fidest press agency su sabato, 9 marzo 2019

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences: Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA
Oppenheimer’s 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit http://www.aurabiosciences.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 28 febbraio 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
8th Annual Leerink Partners Global Healthcare Conference in New York on Friday, March 1, 2019 at 9 a.m. ET.
Cowen and Company 39th Annual Healthcare Conference in Boston on Tuesday, March 12, 2019 at 8 a.m. ET.
A live audio webcast of both presentations can be accessed on the Investors and Media section of the Dicerna website at http://www.investors.dicerna.com. Archived replays will be available on the Company’s website for a period of 90 days after each conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

RealPage to Participate in Upcoming Investor Conferences

Posted by fidest press agency su martedì, 26 febbraio 2019

RealPage, Inc. (NASDAQ:RP), a leading global provider of software and data analytics to the real estate industry, today announced that Steve Winn, Chairman and CEO, will present at the JMP Securities 2019 Technology Conference, to be held in San Francisco on February 26, 2019 at 2:30 p.m. PT.Winn will also present on behalf of RealPage at the Morgan Stanley Technology, Media & Telecom Conference, to be held in San Francisco on February 27, 2019 at 1:30 p.m. PT. Both presentations will be webcast live on the Investor Relations section of the Company’s Web site at http://www.realpage.com.
RealPage is a leading global provider of software and data analytics to the real estate industry. Clients use our platform to improve operating performance and increase capital returns. Founded in 1998 and headquartered in Richardson, Texas, RealPage currently serves over 12,400 clients worldwide from offices in North America, Europe and Asia.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Zayo Executives to Present at February Investor Conferences

Posted by fidest press agency su lunedì, 25 febbraio 2019

Zayo Group Holdings, Inc. (NYSE: Zayo) announced today that executives from the company will present at two investor conferences in February. The links to the live webcasts for the conferences will be made available through the Investor Relations section of the Company’s website at: http://investors.zayo.com.
Matt Steinfort, CFO, will present at the J.P. Morgan Global High Yield & Leveraged Finance Conference at the Loews Miami Beach Hotel in Miami on Tuesday, February 26, 2019.
Dan Caruso, chairman and CEO, will present at the Morgan Stanley Technology, Media and Telecom Conference at the Palace Hotel in San Francisco on Wednesday, February 27, 2019. The presentation will be webcast live at 1:30 p.m. PST.
Zayo Group Holdings, Inc. (NYSE: ZAYO) provides communications infrastructure solutions, including fiber and bandwidth connectivity, colocation and cloud infrastructure to the world’s leading businesses. Customers include wireless and wireline carriers, media and content companies and finance, healthcare and other large enterprises. Zayo’s 130,000-mile network in North America and Europe includes extensive metro connectivity to thousands of buildings and data centers. In addition to high-capacity dark fiber, wavelength, Ethernet and other connectivity solutions, Zayo offers colocation and cloud infrastructure in its carrier-neutral data centers. Zayo provides users with flexible, customized solutions and self-service through Tranzact, an innovative online platform for managing and purchasing bandwidth.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

GreenSky, Inc. to Participate in Upcoming Investor Conference

Posted by fidest press agency su domenica, 24 febbraio 2019

GreenSky, Inc. (“GreenSky” or the “Company”) (NASDAQ: GSKY), a leading financial technology company Powering Commerce at the Point of SaleSM, announced today that the Company will be participating in the following investor conference:
Gerald Benjamin, Vice Chairman and Chief Administrative Officer, will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Florida on Wednesday, March 6th at 9:15 a.m. ET.
Interested parties can listen to the live webcast of the presentation from the investor relations section of the Company’s website at http://www.greensky.com. A replay of the webcast will be available following the event. GreenSky intends to make future announcements of material financial and other information through its investor relations website. GreenSky also will, from time to time, disclose this information through press releases, filings with the Securities and Exchange Commission, conference calls or webcasts.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Western Digital to Participate at Investor Conference

Posted by fidest press agency su domenica, 24 febbraio 2019

Thursday, February 28, 2019 at 10:10AM Pacific / 01:10PM Eastern Morgan Stanley Technology, Media & Telecom Conference.
Western Digital® creates environments for data to thrive. The company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Western Digital® data-centric solutions are comprised of the Western Digital, G-Technology™, SanDisk®, Upthere™ and WD® brands.
Western Digital, the Western Digital logo, G-Technology, SanDisk, Upthere and WD are registered trademarks or trademarks of Western Digital Corporation or its affiliates in the U.S. and/or other countries. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The Trade Desk to Host Investor Day In New York

Posted by fidest press agency su sabato, 9 febbraio 2019

Global advertising technology leader, The Trade Desk (Nasdaq:TTD), plans to host an investor day on March 6, 2019 at the NASDAQ Marketsite in New York City. Key members of The Trade Desk’s leadership team will host a series of presentations beginning at 1:00 PM Eastern Time until 5:00 PM Eastern time.The event, along with supporting materials, can be accessed live or via an archived replay through the Investor Relations section of the Company’s website at investors.thetradedesk.com. Space for the event is limited and, therefore, in-person attendance is by invitation only and advanced registration is required. Analysts and institutional investors interested in attending are encouraged to contact The Trade Desk Investor Relations at ir@thetradedesk.com.The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe, and Asia Pacific.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

2019 BIO CEO & Investor Conference

Posted by fidest press agency su sabato, 9 febbraio 2019

New York Monday, February 11, 2019 3:30pm ET Marriott Marquis (Gramercy room) 2019 BIO CEO & Investor Conference.VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. By http://www.venatorx.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Investor Advisory: Adobe Announces Webcast of Investor Conference Participation

Posted by fidest press agency su venerdì, 8 febbraio 2019

San Francisco, CA Wednesday, Feb. 13, 2019, 5 p.m. Eastern Time Mike Saviage, VP, Investor RelationsAudio of this presentation will be webcast live from Adobe’s Investor Relations website at http://www.adobe.com/ADBE. Conference presentation times are subject to change at the discretion of the conference host. An archive of the webcast will be available for a limited time.Adobe uses its website as a channel of distribution of material company information. Financial, product and other material information regarding Adobe is routinely posted on and accessible at http://www.adobe.com, http://www.adobe.com/ADBE and theblog.adobe.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Alnylam to Webcast Presentations at Upcoming February Investor Conferences

Posted by fidest press agency su giovedì, 7 febbraio 2019

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
21st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at 1:30 pm ET at the Marriott Marquis in New York City
8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 10:30 am ET at the Lotte New York Palace Hotel in New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website, http://www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. ONPATTRO® (patisiran) lipid complex injection, available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi therapeutic. In the EU, ONPATTRO is approved for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of investigational medicines, including three product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,000 people worldwide and is headquartered in Cambridge, MA.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

21st Annual BIO CEO & Investor Conference in New York

Posted by fidest press agency su sabato, 2 febbraio 2019

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 21st Annual BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2019 at 2:15 p.m. ET in the Hudson room (7th floor) at the New York Marriott Marquis.BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Sponsored by the Biotechnology Innovation Organization, the world’s largest biotech trade association, BIO CEO provides a forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: http://www.newron.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »